Cargando…

DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer Cells

BACKGROUND: Down regulation of genes coding for nucleoside transporters and drug metabolism responsible for uptake and metabolic activation of the nucleoside gemcitabine is related with acquired tumor resistance against this agent. Hydralazine has been shown to reverse doxorubicin resistance in a mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Candelaria, Myrna, de la Cruz-Hernandez, Erick, Taja-Chayeb, Lucia, Perez-Cardenas, Enrique, Trejo-Becerril, Catalina, Gonzalez-Fierro, Aurora, Chavez-Blanco, Alma, Soto-Reyes, Ernesto, Dominguez, Guadalupe, Trujillo, Jaenai E., Diaz-Chavez, Jose, Duenas-Gonzalez, Alfonso
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299634/ https://www.ncbi.nlm.nih.gov/pubmed/22427797 http://dx.doi.org/10.1371/journal.pone.0029181

Ejemplares similares

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines
por: Chavez-Blanco, Alma, et al.
Publicado: (2006)

Epigenetic therapy with hydralazine and valproate associated to cisplatin chemoradiation in FIGO stage IIIB. A phase II study
por: Candelaria, Myrna, et al.
Publicado: (2007)

Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells
por: Pérez-Cárdenas, Enrique, et al.
Publicado: (2018)

A proof-of-principle study of epigenetic therapy with hydralazine and magnesium valproate plus doxorubicin cyclophosphamide as neoadjuvant therapy for locally advanced breast cancer
por: Arce, Claudia, et al.
Publicado: (2007)

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
por: Candelaria, Myrna, et al.
Publicado: (2007)

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes
por: Zambrano, Pilar, et al.
Publicado: (2005)

Hydralazine target: From blood vessels to the epigenome
por: Arce, Claudia, et al.
Publicado: (2006)

Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine
por: Segura-Pacheco, Blanca, et al.
Publicado: (2006)

Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer
por: Taja-Chayeb, Lucia, et al.
Publicado: (2006)

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study
por: Chavez-Blanco, Alma, et al.
Publicado: (2005)

A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer
por: Arce, Claudia, et al.
Publicado: (2006)

Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome
por: Taja-Chayeb, Lucia, et al.
Publicado: (2009)

HER2 expression in cervical cancer as a potential therapeutic target
por: Chavez-Blanco, Alma, et al.
Publicado: (2004)

Cancer Progression Mediated by Horizontal Gene Transfer in an In Vivo Model
por: Trejo-Becerril, Catalina, et al.
Publicado: (2012)

A combination of inhibitors of glycolysis, glutaminolysis and de novo fatty acid synthesis decrease the expression of chemokines in human colon cancer cells
por: Schcolnik-Cabrera, Alejandro, et al.
Publicado: (2020)

Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance
por: Trejo-Becerril, Catalina, et al.
Publicado: (2005)

Polymorphisms of the thiopurine methyl transferase gene in healthy and acute lymphoblastic leukemia mestizos
por: Candelaria, Myrna, et al.
Publicado: (2007)

Does Therapeutic Repurposing in Cancer Meet the Expectations of Having Drugs at a Lower Price?
por: Gonzalez-Fierro, Aurora, et al.
Publicado: (2023)

ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma
por: Díaz-Chávez, José, et al.
Publicado: (2022)

Antitumor Effects of Systemic DNAse I and Proteases in an In Vivo Model
por: Trejo-Becerril, Catalina, et al.
Publicado: (2016)

Response to Hydralazine-Valproate in a Patient with Mycosis Fungoides
por: Dueñas-Gonzalez, Alfonso, et al.
Publicado: (2010)

The prince and the pauper. A tale of anticancer targeted agents
por: Dueñas-González, Alfonso, et al.
Publicado: (2008)

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
por: Candelaria, Myrna, et al.
Publicado: (2021)

Molecular characterization of BRCA1 and BRCA2 genes in breast cancer patients under 40 years-old or with familiar cancer history
por: Millan, Silvia Vidal, et al.
Publicado: (2007)

Hydralazine-Induced Vasculitis
por: Gandhi, Pulkit, et al.
Publicado: (2023)

Radiosensitizers in cervical cancer. Cisplatin and beyond
por: Candelaria, Myrna, et al.
Publicado: (2006)

Hydralazine-associated adverse events: a report of two cases of hydralazine-induced ANCA vasculitis
por: Zuckerman, Roman, et al.
Publicado: (2018)

Hydralazine-Induced Vasculitis With Gastrointestinal Pseudomelanosis
por: Novikov, Aleksey, et al.
Publicado: (2014)

Clinical Characteristics of Hydralazine-induced Lupus
por: Timlin, Homa, et al.
Publicado: (2019)

Hydralazine-Induced Isolated Lupus Nephritis
por: Khan, Naseer, et al.
Publicado: (2020)

Hydralazine-Associated Vasculitis and Pulmonary Hemorrhage
por: Strubchevska, Kateryna, et al.
Publicado: (2023)

Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid
por: Mora-García, María de Lourdes, et al.
Publicado: (2006)

Epigenetics of cervical cancer. An overview and therapeutic perspectives
por: Dueñas-González, Alfonso, et al.
Publicado: (2005)

Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice.
por: Bibby, M. C., et al.
Publicado: (1992)

Anti-neoplastic properties of hydralazine in prostate cancer
por: Graça, Inês, et al.
Publicado: (2014)

ANA-Negative Hydralazine-Induced Pericardial Effusion
por: Zeitjian, Vicken, et al.
Publicado: (2017)

Hydralazine-induced vasculitis presenting with ocular manifestations
por: Hawn, Vivian S., et al.
Publicado: (2022)

Tamoxifen-associated vasculitis in a breast cancer patient
por: Candelaria, Myrna, et al.
Publicado: (2007)

The mechanism of hydralazine-induced collagen biosynthesis in cultured fibroblasts
por: Karna, Ewa, et al.
Publicado: (2013)

Anti-TNF-α and hydralazine drug-induced lupus
por: Quaresma, Maria Victória, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_h7j2vcjkbu8e7fqc4nuelu1rie